Tag Archive for Eli Lilly and Company

Lilly and the William Sansum Diabetes Center announce a five-year research collaboration

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Eli Lilly and Company and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education, and care.

“The tremendous burden of diabetes and cardiovascular disease bears a disproportionate weight on Latino families in the United States,” said David Kerr, M.D., FRCPE, director of Innovation and Research for the William Sansum Diabetes Center.  “This collaboration with Lilly will allow us to gain a better understanding of how we can help these families.”

Dr. Kerr added that Latino people comprise 43% of the total population in Santa Barbara County, and rates of cardio-metabolic disease are persistently higher than in the rest of the population due to a combination of factors beyond biological risk, including economics, culture, and education.

For Lilly, the collaboration will provide valuable insights into patients’ unmet needs and aid in the development of interventions that could improve health outcomes for Latino people.

“This is a great opportunity for us to further understand the significant impact of diabetes for Latino families,” said Dara Schuster, M.D., senior director of U.S. Medical Affairs for Lilly Diabetes.  “Through this collaboration, we will learn where the gaps are so we can develop meaningful solutions for the unmet needs.”

SOURCE: Eli Lilly and Company

The post Lilly and the William Sansum Diabetes Center announce a five-year research collaboration appeared first on Naptown Buzz.

Lilly Diabetes Becomes ‘Official Diabetes Health Partner of NASCAR

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

NASCAR® and Lilly Diabetes announced that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates Lilly Diabetes as the “Official Diabetes Health Partner of NASCAR.”

The partnership with Lilly Diabetes builds upon its primary sponsorship of the No. 16 Ford Mustang driven by Roush Fenway Racing’s Ryan Reed, who last weekend won his second career NASCAR XFINITY Series race at Daytona International Speedway. Additionally, as a part of this new partnership, Lilly Diabetes will work with NASCAR on multiple health and wellness initiatives, including launching an editorial series on NASCAR.com.

“As a leader in diabetes care for more than 90 years, we understand the daily challenges that millions of Americans face managing this disease,” said Mike Mason, vice president, U.S., Lilly Diabetes. “Our partnership with NASCAR, along with our continued relationship with Ryan, emphasizes the critical role of ongoing discussions with your doctor about how to best manage the disease.”

As the Official Diabetes Health Partner of NASCAR, Lilly Diabetes – part of Eli Lilly and Company (NYSE: LLY) – will expand its presence in the sport by introducing initiatives that educate fans about the disease. Lilly encourages fans to stay determined and take action to better manage their diabetes by talking to their doctor and making lifestyle changes like exercising and eating healthy. Approximately 30 million Americans have diabetes, and if current trends continue, 1 in 3 U.S. adults will develop diabetes by 20501, making this partnership particularly important.

“The goal of Lilly Diabetes – driving awareness and education – is critical to NASCAR as many of our fans are affected by the disease,” said Lou Garate, NASCAR vice president of partnership marketing. “The rate of Americans developing diabetes continues to rise, and we hope this partnership can help make a positive change in people’s lives.”

Lilly Diabetes has played a significant role in the NASCAR community since 2013, when it first sponsored Roush Fenway Racing driver Ryan Reed and his No. 16 Lilly Diabetes Ford Mustang in the NASCAR XFINITY Series. Ryan has type 1 diabetes and, through his work with Lilly, travels the NASCAR circuit raising awareness about the disease and encouraging fans to take action to better manage their diabetes.

“Our program with Lilly Diabetes is one that touches my life in a significant way, being diagnosed with type 1 diabetes at the age of 17,” said Reed. “I have seen the positive effect our partnership with Lilly Diabetes has had on those impacted by this disease, and I can’t wait to see what NASCAR and Lilly can accomplish together.”

Everyone’s journey with diabetes is different, requiring ongoing, rigorous management that can often be a burden for people with the disease. Through the sponsorship of Reed, and now the partnership with NASCAR, Lilly Diabetes wants to help fans see how small changes can add up to big wins in diabetes management, both on and off the track. Visit www.LillyDiabetes.com/drive today to learn more about Lilly Diabetes and find helpful resources.

SOURCE: Eli Lilly and Company

The post Lilly Diabetes Becomes ‘Official Diabetes Health Partner of NASCAR appeared first on Naptown Buzz.

John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December 31, 2016. Lechleiter will continue on Lilly’s board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. Lilly’s board of directors unanimously elected David A. Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and chief executive officer and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017.

“As Lilly transitions from our recent challenging period of patent expirations to a new era of growth, it is the logical time for a transition in company leadership,” Lechleiter said. “Dave Ricks is a capable, decisive and energetic leader who is very well prepared to succeed me as CEO. He brings to the role broad experience in Lilly’s commercial operations along with an appreciation and understanding of research and development. He previously led Lilly’s business operations in Canada, China, and the U.S. Since 2012, he has successfully guided Lilly’s largest business area, Lilly Bio-Medicines, through a period of profound change. He is well respected inside and outside the company, consistently builds exceptional teams, and sets high standards of performance. Dave is well suited to help Lilly capitalize on the opportunities before it, as well as to confront the inevitable challenges that lie ahead. He will provide outstanding leadership for our company in the coming y

Reflecting on his tenure as Lilly’s top leader, Lechleiter said, “It has been a distinct honor and a privilege to serve this great company as its CEO these past eight years. I wish to thank all of my Lilly colleagues for their unfailing support as well as their extraordinary efforts throughout this period.”

Lechleiter has been the company’s CEO since April 1, 2008, and the chairman of its board of directors since January 1, 2009. He joined Lilly in 1979 as a senior organic chemist in process research and development. In the mid-1980s he served as director of pharmaceutical product development for the Lilly Research Centre Limited in England. He later held roles in project management, regulatory affairs, product development, and pharma operations. In 2005, he was named president and chief operating officer and joined the board of directors.

“The prospect of leading Eli Lilly and Company is at the same time humbling and tremendously exciting,” said Ricks. “Patients, physicians, health-care payers, and society as a whole expect a great deal from us. Together with my Lilly colleagues around the world, I look forward to meeting these expectations and, whenever we can, exceeding them.

“Lilly has the right strategy. We’ve built a strong pipeline and have a promising portfolio of recently approved new medicines. Navigating major patent expirations in recent years, we’ve sharpened our focus and improved our vigilance and agility,” Ricks continued. “Now, we must realize our growth potential in an increasingly challenging global marketplace. We must focus on delivering better and better medicines to the patients who need them, and in so doing, benefit our employees, communities, and shareholders alike.”

Ricks’ successor as president of Lilly Bio-Medicines will be announced at a later date.

Since January 2012, Ricks has served as president of Lilly Bio-Medicines, which encompasses the therapeutic areas of Alzheimer’s disease, urology, immunology, musculoskeletal disease, and pain, as well as the company’s global marketing function. Ricks serves on the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and has served as co-chair of the Trans-Atlantic Business Dialogue.

After joining Lilly in 1996 as a business development associate, Ricks held several management roles in U.S. marketing and sales before moving to Lilly Canada, where he served successively as director of pharmaceutical marketing, national sales director, and general manager. He was subsequently named president and general manager of Lilly China before becoming president of Lilly USA in 2009.

Ricks earned a bachelor’s degree in business from Purdue University and joined Lilly following completion of his MBA from Indiana University. He chairs the Board of Governors for the Riley Children’s Foundation and in 2015 chaired the United Way of Central Indiana’s annual campaign. Ricks also sits on the executive board of the Crossroads of America Council of Boy Scouts of America, and on the Advisory Board of the Purdue University Weldon School of Biomedical Engineering.

Said Ellen Marram, president of The Barnegat Group and Lilly’s lead independent director: “On behalf of Lilly’s entire board of directors, I want to thank John for his strong and steady leadership, and his commitment to the company’s values of integrity, excellence, and respect for people during one of the most difficult and challenging periods in Lilly’s 140-year history. John demonstrated the courage to make important and necessary changes in the company, and, despite near-term financial pressures, he invested robustly in R&D and maintained constant focus on leadership development. As a result, Lilly today is in a position of strength, with excellent prospects for the future based on recent and anticipated new product launches.”

Marram continued: “Following a thorough and rigorous process, the board is pleased to select Dave Ricks to succeed John. In nearly five years as president of Lilly’s Bio-Medicines business, Dave has demonstrated the ability to successfully lead a large global organization engaged in all facets of our business. His experience in the areas of product development, global sales and marketing as well as public policy will ensure continuity and will enable him to lead the company in an ever more complex environment going forward.”

SOURCE: Eli Lilly and Company

The post John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor appeared first on Naptown Buzz.